XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 30 filers reported holding XILIO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $107,000 | – | 36,632 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $4,195,000 | 4.87% |
| AJU IB Investment Co., Ltd. | 667,742 | $1,943,000 | 3.33% |
| Octagon Capital Advisors LP | 2,425,000 | $7,057,000 | 1.22% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $8,164,000 | 0.98% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $8,030,000 | 0.89% |
| Soleus Capital Management, L.P. | 453,660 | $1,320,000 | 0.18% |
| HARVARD MANAGEMENT CO INC | 416,059 | $1,211,000 | 0.15% |
| Rock Springs Capital Management LP | 1,362,878 | $3,966,000 | 0.10% |
| Artal Group S.A. | 450,000 | $1,310,000 | 0.06% |
| Cannell Capital | 17,025 | $50,000 | 0.01% |